01 August 2006
ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy
Agnieszka Jezierska, Wojciech Matysiak, Tomasz MotylMed Sci Monit 2006; 12(8): BR263-273 :: ID: 452847
Abstract
Background:Activated leukocyte cell adhesion molecule (ALCAM/CD166) is a 105-kDa transmembrane glycoprotein linked with cell migration and development and with cancer progression (malignant melanoma, prostate cancer and, very recently, breast cancer). This report is the first evaluation of ALCAM/CD166 in an estrogen-dependent (MCF-7) and a metastatic (MDA-MB-231) breast cancer cell line and a reference breast cell line (HBL-100). The effects of estrogen and anti-estrogen treatment, bcl-2 overexpression, and ALCAM gene silencing on ALCAM/CD166 protein concentration and cell survival were investigated.
Material/Methods: Laser scanning cytometry, confocal microscopy, and Western blotting were used for the determination of ALCAM/CD166 protein and biochemical markers of apoptosis and autophagy.
Results: 17-β-estradiol increased and tamoxifen inhibited ALCAM/CD166 expression and survival of MCF-7 cells. Overexpression of the bcl2 gene in MCF-7 bcl2/neo, MDA-MB-231 bcl2/neo, and HBL-100 bcl2/neo cells significantly increased ALCAM/CD166 expression and was accompanied by decreasing MMP-2 concentrations. Appearance of the ALCAM/CD166 protein was noted in HBL-100 bcl2/neo in contrast to an almost undetectable level in HBL-100 cells. ALCAM gene silencing in MCF-7 cells decreased the concentration of BCL-2 and increased levels of apoptosis (89-kDa PARP, active caspase7) and autophagy (MAP1LC3, Beclin1) markers.
Conclusions:The above results indicate that ALCAM-ALCAM interactions are crucial to the survival and primary site maintenance of breast cancer cells. Impaired expression of ALCAM/CD166 is associated with the induction of two types of programmed cell death, apoptosis and autophagy, in breast cancer cells. This adhesion molecule can therefore be regarded as a potential novel breast cancer indicator and therapeutic target.
Keywords: Tumor Markers, Biological, Tumor Cells, Cultured, Tamoxifen - pharmacology, RNA, Messenger - metabolism, Matrix Metalloproteinase 2 - metabolism, Genes, bcl-2 - genetics, Gene Silencing, Gene Expression Regulation, Neoplastic - drug effects, Activated-Leukocyte Cell Adhesion Molecule - metabolism, Estradiol - pharmacology, Cell Survival - drug effects, Cell Proliferation - drug effects, Breast Neoplasms - pathology
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Laboratory Research
Comparative Evaluation of the Dimensional Accuracy of Silicone-Based Putty Reline Impressions with Differen...Med Sci Monit In Press; DOI: 10.12659/MSM.946537
Clinical Research
Ankle-Brachial Index as a Predictor of Acute Ischemic Cerebrovascular Event After Central Retinal Artery Oc...Med Sci Monit In Press; DOI: 10.12659/MSM.945937
Review article
COL3A1 Gene Polymorphism and Its Impact on Female Pelvic Organ ProlapseMed Sci Monit In Press; DOI: 10.12659/MSM.946367
Clinical Research
Quantifying Gait Asymmetry in Stroke Patients: A Statistical Parametric Mapping (SPM) ApproachMed Sci Monit In Press; DOI: 10.12659/MSM.946754
Most Viewed Current Articles
17 Jan 2024 : Review article 6,962,292
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 699,764
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 22,978
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 17,753
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912